Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a $1.5B+ deal for ex-China rights to a type 2 inflammatory disease drug.
China-based drugmaker Haisco Pharmaceutical has been on a dealmaking tear this summer, and its latest alliance is with two dominant names in biotech.
The biopharma …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with…
AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after…
Haisco licenses inflammatory drug to Sentivera for $40M upfront, $36M stock, $1.46B milestones; FDA OKs ViiV's dolutegravir for…
The ARPA-H program could provide researchers with a roadmap to develop personalized gene editing drugs. Elsewhere, a Botox rival…
AI-focused VC firm raises $800M, Merck's new cholesterol pill, and more biotech news from The Readout
Harbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium
